WAO Symposium on Immunotherapy and Biologics

CHICAGO

13-14 December 2013 – Chicago, IL, United States

Final Program

A meeting of WORLD ALLERGY ORGANIZATION

Follow us on Facebook, Twitter, LinkedIn. Join the conversation: #WA02013

www.worldallergy.org/symposium2013
WISC 2014
WAO International Scientific Conference 2014 and the 41st Annual Meeting of the Brazilian Association of Allergy and Immunology (ASBAI)

Advancing the borders of allergy: From treatment to prevention by targeting the environment, infections and the susceptible patient

Rio de Janeiro, Brazil
6-9 December 2014

www.worldallergy.org/wisc2014
# Contents

- Invitation to Participate ................................................................. 3
- 2012-2013 WAO Board of Directors................................................. 3
- WAO Symposium Steering Committee ........................................... 3
- Symposium Information, A-Z .......................................................... 4-7
- Scientific Program Information ....................................................... 8
- Floorplan ...................................................................................... 8
- Program-At-A-Glance ................................................................... 9

## Scientific Program

- Friday, 13 December 2013 ............................................................ 13-20
- Saturday, 14 December 2013 ....................................................... 22-28

- Exhibit Hall Directory .................................................................. 30
- Collaborating & Media Partners ..................................................... 32
- Speaker, Author and Chairperson Index ........................................ 35-36
- WAO Member Societies ................................................................ 40
- Symposium Sponsors ................................................................... Back Cover

# About WAO

The World Allergy Organization (WAO) is an international alliance of 92 regional and national allergy, asthma and clinical immunology societies. Through collaboration with the Member Societies, WAO provides a wide range of educational and outreach programs, symposia and lectureships to allergists/immunologists around the globe and conducts initiatives relating to clinical practice, service provision, and physician training in order to better understand and address the challenges facing allergists/immunologists worldwide.

## Mission

WAO’s mission is to be a global resource and advocate in the field of allergy, asthma and clinical immunology advancing excellence in clinical care through education, research and training as a worldwide alliance of allergy, asthma and clinical immunology societies.

## Contact Us

**WAO Secretariat**

World Allergy Organization  
555 East Wells Street, Suite 1100  
Milwaukee, WI 53202 United States  
Phone: +1 414 276 1791  
Fax: +1 414 276 3349

**Inquires**

symposium@worldallergy.org

**WAO Symposium Website**

www.worldallergy.org/symposium2013
Check out the updated White Book on Allergy!

WAO
White Book on Allergy
Update 2013

worldallergy.org
Welcome to the WAO Symposium!

Dear Colleagues,

On behalf of the World Allergy Organization (WAO) Board of Directors, it is our great pleasure to welcome you to the WAO Symposium on Immunotherapy and Biologics in Chicago, IL, United States.

The purpose of this two day meeting, focusing on Immunotherapy and Biologics, is to bring basic and translational scientists, clinical immunologists, allergists and researchers together to expand this exciting field.

The scientific program consists of lectures from the top international experts in the field as well as free communications that are presented during the Poster Sessions. Our aim is to summarize what is scientifically known, learn about the cutting-edge research and to reach a consensus about the unmet needs of Immunotherapy and Biologics.

Once again, thank you for attending the WAO Symposium on Immunotherapy and Biologics.

Welcome to Chicago!

Sincerely,

Ruby Pawankar, President, WAO

Lanny J. Rosenwasser, President-Elect, WAO
Abstracts
Accepted abstracts that were submitted for the WAO Symposium have been placed in Poster Sessions on 13 and 14 December. Poster numbers are listed to the left of the abstract title in this Final Program. This number can be used to view or download abstracts using the Online Scientific Program (www.worldallergy.org/program). For abstract certificates, please visit the registration desk.

Abstract USB
Accepted abstracts that were submitted for the WAO Symposium are also available on the Abstract USB, which is available for all registered delegates upon check-in at the Registration Desk.

Abstract USB sponsored by:

Abstract Distribution
Previously unpublished abstracts that were accepted for presentation at the WAO Symposium will be published as a supplement to the WAO Journal (www.waojournal.org).

Badges
Each delegate receives a name badge upon check-in at the Registration Desk. The badge is the official Symposium document and should be worn at all times in order to gain entry to the session rooms and other events. Please note that access to any of the Symposium areas or events is not possible without an official name badge.

In order to comply with security requirements, delegates are expected to wear their name badges at all times in all areas. If you lose your badge, a new one can be purchased at the Registration Desk for $50 USD with photo identification.

Certificate of Attendance
Delegates of the WAO Symposium receive a Certificate of Attendance upon check-in at the Registration Desk.

Continuing Medical Education Credits
Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this live activity for a maximum number of 12.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of Allergy, Asthma and Immunology (AAAAI) and the World Allergy Organization. The AAAAI is accredited by the ACCME to provide continuing medical education for physicians.

Instructions for Claiming CME Credits
Please visit http://education.aaaai.org/WAO2013

Pre-Test:
- Click “yes” to enroll in the activity
- Login with your AAAAI Username and Password.
  - New users/Forgot your password: type your email address in the field below username and password and click “continue”. You will receive an email with a link to reset/create your login.
- Once logged in, you will be directed back to the registration page for the “2013 Symposium on Immunotherapy and Biologics”.
- Click the red “Take Course” button
- Click on “CME Info Begin” and type the enrollment key: J227
- Review the CME Info
- Complete the Pre-test (mandatory to claim credit)

Post-Test:
After attending the Symposium, you will receive an email and be asked to complete a Post-Test and evaluation. Once this is completed, you will claim your CME Credits. No certificates are given on-site.

For any inquiries you may have throughout the CME process, please contact: cme@aaaai.org.

Coffee Breaks
Coffee Breaks on 13 and 14 December are included in the registration fee and are available during designated times. Coffee breaks are located in the Michigan Ballroom.

DRESS
Dress for the Symposium is business casual.

Exhibit Hall
A commercial exhibit is located in the Michigan Ballroom.

Exhibit Hall Open Hours:
- 13 December 2013: 09:30 - 15:30
- 14 December 2013: 09:30 - 15:30

Please view the Exhibit Directory on page 30 for more information.
Evaluations
Delegates are able to provide feedback on their experiences at the Symposium in two ways:
• Delegates can provide feedback on faculty members and the sessions they attend by using paper evaluation forms. Paper evaluation forms are handed out when entering session doors and can be collected when exiting. Completed evaluations can also be turned in at the Registration Desk.
• Delegates will be asked to provide input on the educational program through the online CME Claim System when claiming credit for participation.

Guests and Children
Delegates are asked to refrain from bringing guests and children to the scientific sessions of the WAO Symposium.

Handouts
Handouts are provided by the Symposium speakers and should be used to enhance your learning experience. Handouts include reading lists, outlines of presentations and PowerPoint slides. To view or download the speaker handouts, you may use the Online Scientific Program (www.worldallergy.org/program).
To find a specific handout, you can search by the handout number (displayed on the left side of the talk title in this Final Program), by author name, session, talk title or topic.

Handouts on USB
Handouts are also available on the Handout USB, which are available for all registered delegates upon check-in at the Registration Desk.

Insurance/Liabilities and Disclaimer
WAO cannot be held liable for personal injuries or for loss of or damage to property incurred by delegates or guests at the 2013 WAO Symposium on Immunotherapy and Biologics, including those participating in related events. Delegates and guests are encouraged to purchase insurance to cover loss incurred in the event of cancellation, medical expenses or damage to or loss of personal effects when traveling outside of their own countries.

The materials presented at this continuing medical education activity are made available for educational purposes only. The materials are not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed, but rather are intended to present an approach, view, statement, or opinion of the faculty that may be helpful to others who face similar situations.
Language
The official language of the Symposium is English. All sessions are conducted in English.

Lost and Found
Please visit the Registration Desk for any lost and found items.

Lost Badges
If you lose your badge, a new one can be purchased at the Registration Desk for $50 USD with photo identification.

Mobile Phone Policy
Use of mobile phones is strictly prohibited within the scientific session rooms. Please ensure that your mobile phone is silenced while you are in the Symposium venue.

Networking Event

Welcome Reception – Tickets Required
Friday, 13 December 2013
18:00 – 19:00
Westin – Michigan Avenue, 16th Floor, Chicago Ballroom
Join fellow delegates for a networking event on the first night of the Symposium. Hors d’oeuvres and beverages are provided. The reception is included in the registration fee, but delegates who chose not to attend benefited from a reduced registration fee.

Tickets are required for entrance and are included with the Symposium badge.

Additional Welcome Reception tickets can be purchased at the On-Site Registration Desk for $30 USD.

Networking Lounge
A Networking Lounge is located on the 2nd Floor of the Westin – Michigan Avenue in the Ontario room.

Networking Lounge Open Hours:
13 December 2013: 08:00 – 18:00
14 December 2013: 08:00 – 17:00

No Smoking Policy
Smoking is not permitted during any Symposium activity or event.

Parking
The Westin – Michigan Avenue offers on-site, covered, valet parking for $59 USD per night. Overnight guests enjoy in and out privileges. Please note that self-parking is not available on-site.

Payments
On-site payments can be made by credit card (Visa, MasterCard, American Express, Diners Club or Discover) or cash (USD only).

Photography
By registering to attend the 2013 WAO Symposium on Immunotherapy and Biologics, you acknowledge and agree that official photographs taken during the meeting may be used for future WAO promotional purposes and may be shared in the WAO Photo Gallery and post-event news updates. Please contact the WAO Secretariat if you have any concerns with this policy. Personal photography is allowed, but please refrain from flash photography during the sessions.

Poster Sessions
The Poster Sessions are held in the Michigan Ballroom. Please check the scientific program schedule for exact times. Presenting Authors stand next to their posters and are available for discussion and questions.

Poster Hall Open Hours:
13 December 2013: 09:30 – 15:30
14 December 2013: 09:30 – 15:30

Poster Set: Please be sure to set-up posters on the appropriate poster boards on Thursday, 12 December from 15:00 – 19:00 or Friday, 13 December from 07:00 – 09:00. Posters will remain on display throughout the Symposium, and must be dismantled between 15:30 – 17:30 on Saturday, 14 December. Posters not dismantled by 17:30 on Saturday, 14 December will be discarded.

Refunds
There are no refunds for on-site payments.

Registration
The Registration Desk is located on the 2nd Floor of the Westin – Michigan Avenue, Superior East.

Registration Open Hours:
12 December 2013: 15:00 – 19:00
13 December 2013: 07:00 – 18:00
14 December 2013: 07:00 – 17:00

Registration includes:
Admission to all Scientific Sessions
Admission to Poster Hall
Admission to Exhibit Hall
Certificate of Attendance
Coffee Breaks
Welcome Reception*

*Delegates who chose not to attend the Welcome Reception benefited from a reduced registration fee.
Social Media

WAO’s social media allows you to interact and stay connected with WAO and other attendees before, during and after the meeting.

Use the hashtag #WAO2013 for your comments, questions, photos or to see what everyone else is talking about.

Twitter: @worldallergy
Facebook: facebook.com/worldallergyorg
LinkedIn: linkedin.com/company/world-allergy-organization

Speaker Disclosures

Copies of speakers’ disclosure information is available at the Registration Desk.

Speaker Ready Room

The Speaker Ready Room is located on the 2nd Floor of the Westin – Michigan Avenue in the Huron C room.

Speakers are asked to check-in, drop off and finalize their slide presentations. It is requested that speakers visit the Speaker Ready Room at least one hour before the beginning of their session. Speakers making early morning presentations should check-in the previous day.

Speaker Ready Room Open Hours:
- 12 December 2013: 15:00 – 19:00
- 13 December 2013: 07:00 – 17:00
- 14 December 2013: 07:00 – 15:30

Special Dietary Requirements

If items on the daily, pre-arranged menu do not meet your special dietary requirements (e.g., allergies, kosher) an alternative option can be made available. Please notify a WAO staff member at the Registration Desk to ensure arrangements are made. Special arrangements require at least 24 hours advance notice.

Venue

The WAO Symposium on Immunotherapy and Biologics is taking place on the 2nd Floor of the Westin – Michigan Avenue.

Westin - Michigan Avenue
909 North Michigan Ave.
Chicago, IL, United States
Phone: 1-866-716-8104
www.thewestinmichiganavenue.com

Wi-Fi

Wireless internet access is provided on the 2nd Floor of the Westin – Michigan Avenue for all delegates of the WAO Symposium.

Network: Westin Meeting Rooms
Password: teva

Internet access sponsored by:
Educational Objectives

- To provide insights into what is already known about Immunotherapy and Biologics.
- To highlight the most recent advances and cutting-edge research in the field.
- To provide a forum for discussion and learning for those in attendance.
- To identify unmet needs and areas of research priorities.

Session Types

Plenary Sessions
Plenary presentations set the stage with context and background through overviews and literature reviews to define unmet needs.

Special and Keynote Lectures
Special and Keynote Lectures offer attendees the opportunity to attend a 30 minute lecture on a specific topic from one of the key opinion leaders in the field.

Biologics Track Sessions
Biologics Track sessions address more specific topics in the field of Biologics, providing the opportunity for in-depth and detailed exploration. Discussion among participations is encouraged.

Immunotherapy Track Sessions
Immunotherapy Track sessions address more specific topics in the field of Immunotherapy, providing the opportunity for in-depth and detailed exploration. Discussion among participations is encouraged.

Poster Sessions
Accepted abstracts are presented during Poster Sessions. Presenting Authors stand with their posters, answer questions and discuss their research.

Floorplan

Westin - Michigan Avenue, 2nd Floor
<table>
<thead>
<tr>
<th>Time</th>
<th>13 December 2013</th>
<th>14 December 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Plenary Session: Novel Insights in the Biology of Allergic Responses in Immunotherapy</td>
<td>Plenary Session: Novel Insights in the Biology of Allergic Responses in Immunotherapy</td>
</tr>
<tr>
<td>8:15</td>
<td>Great Lakes Grand Ballroom</td>
<td>Great Lakes Grand Ballroom</td>
</tr>
<tr>
<td>8:30</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>8:30</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>8:45</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>9:00</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>10:30</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>10:45</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>11:00</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>11:30</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>11:45</td>
<td>Coffee Break: Michigan Ballroom</td>
<td>Coffee Break: Michigan Ballroom</td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>12:15</td>
<td>Lunch Break</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>12:30</td>
<td>WAO Session: WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
<td>WAO Session: WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
</tr>
<tr>
<td>12:45</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
</tr>
<tr>
<td>13:00</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
</tr>
<tr>
<td>13:15</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
</tr>
<tr>
<td>13:30</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
</tr>
<tr>
<td>13:45</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
<td>WAO White Book Update and Allergen and Adherence Manifestos Launch</td>
</tr>
<tr>
<td>14:00</td>
<td>Biologics Track 2: Novel Anti-Cytokines Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 2: Sublingual Immunotherapy Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>14:15</td>
<td>Biologics Track 2: Novel Anti-Cytokines Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 2: Sublingual Immunotherapy Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>14:30</td>
<td>Biologics Track 2: Novel Anti-Cytokines Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 2: Sublingual Immunotherapy Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>14:45</td>
<td>Biologics Track 2: Novel Anti-Cytokines Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 2: Sublingual Immunotherapy Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>15:00</td>
<td>Biologics Track 2: Novel Anti-Cytokines Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 2: Sublingual Immunotherapy Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>15:15</td>
<td>Biologics Track 2: Novel Anti-Cytokines Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 2: Sublingual Immunotherapy Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>15:30</td>
<td>Biologics Track 2: Novel Anti-Cytokines Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 2: Sublingual Immunotherapy Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>15:45</td>
<td>Biologics Track 2: Novel Anti-Cytokines Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 2: Sublingual Immunotherapy Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>16:00</td>
<td>Biologics Track 3: New Directions in Immunotherapy Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 3: Immunotherapy Targets for Food Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>16:15</td>
<td>Biologics Track 3: New Directions in Immunotherapy Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 3: Immunotherapy Targets for Food Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>16:30</td>
<td>Biologics Track 3: New Directions in Immunotherapy Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 3: Immunotherapy Targets for Food Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>16:45</td>
<td>Biologics Track 3: New Directions in Immunotherapy Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 3: Immunotherapy Targets for Food Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>17:00</td>
<td>Biologics Track 3: New Directions in Immunotherapy Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 3: Immunotherapy Targets for Food Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>17:15</td>
<td>Biologics Track 3: New Directions in Immunotherapy Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 3: Immunotherapy Targets for Food Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>17:30</td>
<td>Biologics Track 3: New Directions in Immunotherapy Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 3: Immunotherapy Targets for Food Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>17:45</td>
<td>Biologics Track 3: New Directions in Immunotherapy Great Lakes Grand Ballroom East</td>
<td>Immunotherapy Track 3: Immunotherapy Targets for Food Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>18:00</td>
<td>Welcome Reception Chicago Ballroom (16th Floor)</td>
<td>Welcome Reception Chicago Ballroom (16th Floor)</td>
</tr>
<tr>
<td>18:15</td>
<td>Welcome Reception Chicago Ballroom (16th Floor)</td>
<td>Welcome Reception Chicago Ballroom (16th Floor)</td>
</tr>
<tr>
<td>18:30</td>
<td>Welcome Reception Chicago Ballroom (16th Floor)</td>
<td>Welcome Reception Chicago Ballroom (16th Floor)</td>
</tr>
<tr>
<td>18:45</td>
<td>Welcome Reception Chicago Ballroom (16th Floor)</td>
<td>Welcome Reception Chicago Ballroom (16th Floor)</td>
</tr>
</tbody>
</table>
Publish your next research article to global readers in

WAO journal

WORLD ALLERGY ORGANIZATION

Editor-in-Chief:
Lanny Rosenwasser (USA)

Reasons to publish in World Allergy Organization Journal

- Official Journal of the World Allergy Organization
- Unrestricted access ensures wide dissemination of articles
- Open access complies with funders’ mandates such as NIH and Wellcome Trust
World Allergy Organization Journal publishes original research, clinical reviews, position papers, and epidemiological studies that contribute to current knowledge in patient care.

World Allergy Organization Journal is advised by an expert Editorial Board.

Editor-in-Chief:
Lanny Rosenwasser (USA)

Regional Section Editors
Africa/Middle East:
Yehia El Gamal (Egypt)
Menachem Rottem (Israel)

Asia Pacific:
Peter Le Souef (Australia)
Hirohisa Saito (Japan)

Europe:
Sergio Bonini (Italy)
Tari Haathela (Finland)

Latin America:
Luis Caraballo (Columbia)
Mario Sánchez-Borges (Venezuela)

North America:
Michael Blaiss (USA)
Michael Kaliner (USA)

Editorial Board Members:
Rob Aalberse (Netherlands)
Cezmi Akdis (Switzerland)
Zeinab Awad El-Sayed (Egypt)
Thomas Casale (USA)
Motohiro Ebisawa (Japan)
Daniel Ein (USA)
Anne Ellis (Canada)
Sandra González-Díaz (Mexico)
Juan Carlos Ivancevich (Argentina)
Erika Jensen-Jarolím (Austria)
Yin Jia (China)
Marek Jutel (Switzerland)

Ömer Kalayci (Turkey)
Bee Wah Lee (Singapore)
Dean Metcalfe (USA)
Hugo Neffen (Argentina)
Yoshimichi Okayama (Japan)
Hae-Sim (South Korea)
Ruby Pawankar (Japan)
Todor A Popov (Bulgaria)
Paul Potter (South Africa)
Harald Renz (Germany)
Joaquin Sastre Domínguez (Spain)
Glenis Scadding (UK)
Revaz Sepiashvili (Russia)
C Paolo Tassinari (Venezuela)
Massimo Triggiani (Italy)
Pakit Vichyanond (Thailand)
Anahi Yañez (Argentina)

Read the latest research and submit your manuscript online at
www.waojournal.org

BioMed Central
The Open Access Publisher
www.biomedcentral.com
Subscribe JIACI!

www.jiaci.org

- Impact Factor 2011: 2,269
- Site visitors/year: 298,271 visitors
- Downloaded articles/year: 318,997 articles
- Pages views/year: 1,015,333 pages
- Average daily visitors: 817

And we are growing!

ESMON Publicidad, S.A.
Balmes 209, 3º 2ª
08006 Barcelona, Spain
Tel. +34 93 215 90 34 - Fax: +34 93 487 40 64
E-mail: monica@esmonpublicidad.com
**Scientific Program**

**Friday, 13 December 2013**

**08:00 - 10:00**  
**Plenary Session**  
**Great Lakes Grand Ballroom**

**NOVEL INSIGHTS IN THE BIOLOGY OF ALLERGIC RESPONSES IN IMMUNOTHERAPY**

**Chairpersons:**  
Ruby Pawankar (Japan)  
Lanny J. Rosenwasser (United States)

**Learning Objectives:**
- Explain the approach to personalized medicine and targets for biologics in the treatment of disease.
- Illustrate the biologic basis of allergic diseases.
- Identify the mechanisms and clinical utility of allergy immunotherapy and immune tolerance.
- Outline the newer and up-to-date clinical approaches to allergen immunotherapy.

08:00 - 08:05  
**Welcoming Remarks**

08:05 - 08:30  
1-1 **Personalized Medicine in Allergy and Asthma | Elliot Israel (United States)**

**Learning Objectives:**
- Indicate how genetic variation and endotypes influence responses to pharmacotherapy.
- Deduce how component resolved allergen diagnosis and the use of allergens tailored to an individual’s sensitization creates a unique opportunity for personalized medicine in allergy.
- Compare and contrast the different inflammatory phenotypes of asthma and other chronic allergic diseases with involvement of different causative pathways and how it will lead to greater precision in targeting therapeutics, especially biologics.

08:30 - 08:55  
1-2 **Biologic Basis of the Allergic Response | Bruce S. Bochner (United States)**

**Learning Objectives:**
- Analyze the cellular and molecular basis of allergic inflammation and disease.
- Illustrate the relationship of allergic immune responses to allergic disease.
- Indicate the potential biologic targets for treatment in immunotherapy.

08:55 - 09:20  
1-3 **Overview of Allergen Immunotherapy and Tolerance | Cezmi Akdis (Switzerland)**

**Learning Objectives:**
- Illustrate how cellular and molecular mechanisms of allergen tolerance is induced by allergen-specific immunotherapy.
- Identify the mechanisms of immune response in allergen reactivity.
- Recognize the role of allergen immunotherapy in altering responses to allergens.
- Define the mechanisms of immune tolerance in allergen immunotherapy.

09:20 - 09:45  
1-4 **New Treatments for Allergen Immunotherapy | Mübeccel Akdis (Switzerland)**

**Learning Objectives:**
- Summarize the clinical parameters for successful allergen immunotherapy.
- Evaluate the new approaches to treatment of allergic disease with allergen immunotherapy.
- Recognize new techniques for allergen immunotherapy which enhance successful treatment.

09:45 - 10:00  
**Discussion**

**10:00 – 10:30**  
**Coffee Break**  
**Michigan Ballroom**
OVERVIEW AND NEWER USES OF ANTI-IGE

Chairpersons:
Claus Bachert (Belgium)
Nelson Rosario-Filho (Brazil)

Learning Objectives:
• Explain the versatile roles of IgE in regulating allergic airway inflammation.
• Illustrate the rationale of IgE blockade in the treatment of allergic disease.
• Analyze the benefits and indications of anti-IgE monoclonal antibody treatment in asthma, food allergy and urticaria.

10:30 - 10:35  Welcoming Remarks
10:35 - 10:55  1-5 The Role of IgE–Receptors in Airway Inflammation and Remodelling | Ruby Pawankar (Japan)
Learning Objective:
• Explain the versatile roles of IgE and its interactions with the high affinity IgE receptor in regulating the cellular and molecular mechanisms of allergic airway inflammation.

10:55 - 11:15  1-6 New Strategies with Anti-IgE in Allergic Diseases | Stephen T. Holgate (United Kingdom)
Learning Objectives:
• Illustrate the rationale of IgE blockade in the treatment of allergic disease.
• Analyze the benefits and indications of anti-IgE monoclonal antibody (omalizumab) in asthma.
• Determine which of these patients might benefit most from omalizumab.

11:15 - 11:35  1-7 Oral Immunotherapy and Anti-IgE Antibody–Adjunctive Treatment for Food Allergy | Dale Umetsu (United States)
Learning Objective:
• Interpret the progress in developing oral immunotherapy (OIT) for food allergy, including a novel approach utilizing anti-IgE monoclonal antibody (omalizumab) in combination with OIT, especially in terms of safety and efficacy.

11:35 - 11:55  1-8 Anti-IgE in Chronic Urticaria | Sarbjit Saini (United States)
Learning Objective:
• Classify and recognize the benefits of the anti-IgE monoclonal antibody (omalizumab) in inducing and maintaining long-term remission for patients with severe chronic urticaria.

11:55 - 12:00  Discussion
OVERVIEW OF IMMUNOTHERAPY

Chairpersons:
Suwat Benjaponpitak (Thailand)
Mario Sanchez Borges (Venezuela)

Learning Objectives:
• Summarize the history of the practice of immunotherapy, including the challenges and unmet needs.
• Express the different aspects of allergen immunotherapy in the United States and Europe.
• Distinguish between the allergen immunotherapy adverse reactions of subcutaneous immunotherapy or sublingual immunotherapy to be used across the world.
• Deduce the risks and how to manage and prevent anaphylaxis in patients on immunotherapy.

10:30 - 10:35 Welcoming Remarks
10:35 - 10:55 1-9 Historical Perspective and Current Standards in Immunotherapy: Challenges and Unmet Needs | Richard F. Lockey (United States)
Learning Objectives:
• Identify sentinel allergen immunotherapy advancements, particularly over the past 45 years.
• Review allergen immunotherapy treatment standards for optimal outcomes.
• Recognize promising allergen immunotherapy innovations yet to come.

10:55 - 11:15 1-10 Subcutaneous Immunotherapy: Perspectives of Treatment Practices in the United States and Europe | Oliver Pfaar (Germany)
Learning Objectives:
• Compare and analyze the different aspects of allergen immunotherapy clinical practice on the two continents in order to create a common language.
• Debate treatment practices in the United States and Europe through a pro and con analysis to create harmonization.

11:15 - 11:35 1-11 Speaking the Same Language: Grading System for Subcutaneous Immunotherapy Systemic Reaction | Linda Cox (United States)
Learning Objectives:
• Characterize sublingual and subcutaneous immunotherapy adverse reactions: types and incidence per published studies, post marketing surveillance and surveys.
• Define risk factors for immunotherapy adverse reaction.
• Apply the WAO Grading Systems for subcutaneous Immunotherapy / sublingual immunotherapy systemic reactions and sublingual immunotherapy local reactions.
• Identify a common language through the new WAO initiatives on Allergen Immunotherapy Adverse Reactions of Subcutaneous Immunotherapy or Sublingual Immunotherapy to be used across the world to indicate those effects.

11:35 - 12:00 1-12 Management of Anaphylaxis during Immunotherapy | Phil Lieberman (United States)
Learning Objectives:
• Evaluate the inherent risk of administering an allergen to an individual who is sensitized to the substance administered.
• Express the effective measures to reduce the risk of these events.
• Discuss how to manage and prevent anaphylaxis in patients on immunotherapy.

12:00 – 12:30 Lunch Break
12:15 – 13:15 WAO Session |  

WAO WHITE BOOK UPDATE AND ALLERGEN AND ADHERENCE MANIFESTOS LAUNCH

12:15 - 12:45 WAO White Book on Allergy Update | Ruby Pawankar (Japan)
12:45 - 12:53 Question and Answer
12:53 - 12:59 Manifesto on Adherence | G. Walter Canonica (Italy)
12:59 - 13:04 Question and Answer
13:04 - 13:10 Manifesto on Allergens | G. Walter Canonica (Italy)
13:10 – 13:15 Question and Answer

This session is not eligible for CME credits.
Call for your submission of manuscript. -FEEL FREE!-

No manuscript processing fee!
No review processing charge!
No color figure production payment!
Scientific Program

Friday, 13 December 2013 — continued

12:30 – 13:30  Poster Session 1  Michigan Ballroom

Chairperson:
Michael Foggs (United States)

1000  Efficacy and Safety of Specific Sublingual Immunotherapy with Carbamylated Allergoid Tablets of Ragweed Pollen: A Dose-Ranging Study | Elide Pastorello (Italy), Gianna Moscato (Italy), Daniele Berra (Italy), Anna Tosi (Italy), Marina Mauro (Italy), Enrico Compalati (Italy) and Claudio Ortolani (Italy)

1001  ALLERGENIUS®: an Expert System for the Interpretation of Allergen Microarrays | G. Walter Canonica (Italy), Giovanni Passalacqua (Italy) and Gianni Melioli (Italy)

1002  Galectin–3 as Predictive Biomarker of Airways Remodeling Modulation in Omalizumab Treated Severe Asthma Patients | Pierluigi Mauri (Italy), Annamaria Riccio (Italy), Rossana Rossi (Italy), Dario Di Silvestri (Italy), Louise Benazzi (Italy), Laura De Ferrari (Italy), Roberto W Dal Negro (Italy) and G. Walter Canonica (Italy)

1003  Omalizumab is Effective in Allergic and Nonallergic Patients | Claus Bachert (Sweden) and Philippe Gevaert (Belgium)

1004  The Effect of B7–H3 on CD4+ T Lymphocyte Activation In Vitro | Mi Eun Kim (Korea), Dong Hwan Kim (Korea), Ju Hwa Yoon (Korea) and Jun Sik Lee (Korea)

1005  Analysis of the mechanism of the allergen immunotherapy in Japanese cedar pollinosis | Takenori Haruna (Japan), Mitsuhiko Okano (Japan), Takaya Higaki (United States), Shin Kariya (Japan) and Kazunori Nishizaki (Japan)

1006  Baicalin From Scutellaria baicalensis Impairs Th1 Polarization Through Inhibition of Dendritic Cell Maturation | Mi Eun Kim (Korea), Dong Hwan Kim (Korea), Ju Hwa Yoon (Korea), Meike Mueller (German), Holger Ziehr (Germany), Dietrich Haeffner (Germany), Norbert Krug (Germany) and Wolfgang Koch (Germany)

1007  Universal Allergen Particle Generation for Inhaled Allergen Challenges in the Fraunhofer Environmental Challenge Chamber (ECC) | Jens M Hohlfeld (Germany), Katrin Lueer (Germany), Heike Biller (Germany), Horst Windt (Germany), Philipp Badorrek (Germany), Meike Mueller (Germany), Holger Ziehr (Germany), Dietrich Haeffner (Germany), Norbert Krug (Germany) and Wolfgang Koch (Germany)

1008  Dialyzable Leukocyte Extracts as Adjuvant Treatment for Allergic Rhinitis | Toni Angela Homberg (Mexico), Rodolfo Ivan Lara (Mexico), Sonia Mayra Pérez-Tapia (Mexico) and María Del Carmen Jiménez Martínez (Mexico)

1009  AAAAI Survey on Allergen Immunotherapy (AIT) in Patients with Specific Medical Conditions | Desirée Larenas-Linnemann (Mexico), David Hauswirth (United States), Christopher Calabria (United States), Lawrence Sher (United States) and Matthew Rank (United States)

1010  AAAAI Membership Experience with Venom Immunotherapy in Chronic Medical Conditions, Pregnancy and Young Children | Christopher Calabria (United States), David Hauswirth (United States), Matthew Rank (United States), Lawrence Sher (United States) and Desirée Larenas-Linnemann (Mexico)

1011  Potential Immunogenetic Associations Between Atopy and Metabolic Syndrome In Children | Damian Palafox (Mexico), Brenda Tello-López (Mexico) and Laura Vidal (Mexico)

1012  Safety and Efficacy Of Omalizumab In 10 Children With Asthma and Other Allergic Comorbidities | Rita Aguiar (Portugal), Pedro Silva (Portugal), Fátima Duarte (Portugal), Ana Mendes (Portugal), Ana Célia Costa (Portugal) and Manuel Pereira Barbosa (Portugal)

1013  IL–4R Alpha Antibody Inhibits IgE Production and Airway Remodeling In Mouse Model Of House Dust Mite–Induced Eosinophilic Asthma | Ludmila Kelly (United States), Xia Liu (United States) and Linda Williams (United States)

1014  Omalizumab Efficiency In Patients With Allergic Rhinitis and Chronic Sinusitis | Sandra Nora Gonzalez-Diaz (Mexico) and Lorena Rangel-Garza (Mexico)

1015  A Semi-rational Approach to Obtain a Thermostable Ionic Liquid Tolerant Bacterial Laccase Through Π-Type Interactions | Farideh Ghazi (Iran), Bahareh Dabirmanesh (Iran) and Hanieh Dabirmanesh (United States)

1016  A Novel Peanut Allergoid Is Safe and Effective In a Murine Immunotherapy Model For Peanut Allergy | Hans Van Schijndel (Netherlands)

1017  Preclinical and Clinical Findings: Role Of Periostin, IL–13, Lebrikzumab and Corticosteroid Resistance | Robert Townley (United States), Pradeep Gendapodi (United States), Swati Agrawal (United States), Yang Wang (United States), Tony Romero (United States) and Peter Abel (United States)

1018  Evaluation Of CCR3 As a Basophil Activation Marker | Aaruni Khanolkar (United States), Steven Burden (United States), Benjamin Hansen (United States), Andrew Wilson (United States), Gregory Philipps (United States) and Harry Hill (United States)

WAO Abstract Award
1019 | Novel Allergy Vaccine Delivery System For Poison Ivy Urushiol (PI) and Peanut (PN)  
Robert Coifman (United States) and Catherine Yang (United States)

1020 | Efficacy and Safety Of Sublingual Specific Immunotherapy With Pru p 3 In a Portuguese Population - Clinical and Immunological Evaluation During 12 Months  
Ana Célia Costa (Portugal), Fátima Duarte (Portugal), Elisa Pedro (Portugal), Alcinda Melo (Portugal), Manuel Pereira Barbosa (Portugal) and Conceição Santos (Portugal)

1021 | Use Of Paper Filter Discs For Measurement Of Local Biomarkers Of Nasal Mucosal Inflammation  
Margot Berings (Belgium), Lien Calus (Belgium), Lien Devuyst (Belgium), Thibaut Van Zele (Belgium), Natalie De Ruyck (Belgium), Claus Bachert (Belgium, Sweden) and Philippe Gevaert (Belgium)

1022 | Angioedema and Angioedema Management From Asteria II: A Clinical Trial To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Who Remain Symptomatic Despite H1 Antihistamine Treatment  
James Zazzali (United States), Karin Rosen (United States), Hsin-Ju Hsieh (United States) and Charlotte Kenneigh (United States)

1023 | Dupilumab Suppresses Th2 Inflammation In Adult Asthma and Atopic Dermatitis  
Brian Swanson (United States), Jeffrey Ming (United States), Haobo Ren (United States), Lin Wang (United States), Sally Wenzel (United States), Lisa Beck (United States), Thomas Diciccio (United States), Yongtao Li (United States), Pavel Belomestnov (United States), Neil Graham (United States), Gianluca Pirozzi (United States), Jennifer Hamilton (United States) and Linda Williams (United States)

1024 | Accelerated Healing Of Full-Thickness Cutaneous Wound Using Purified Apitoxin From Asiatic Honey Bee (Apis cerana Fabricius)  
Hua Chen (China), Huili Sun (China), Jianyu Pan (China), Bingna Cai (China), Peng Wan (China) and Deke Chen (China)

1025 | Introduction To The Clinical Practice Of Molecular Allergology  
Guy Tropper (Canada)

1026 | Randomized Clinical Trial to Evaluate Oral Dializable Leukocyte Extracts as Immunemodulator Treatment in Atopic Dermatitis  
Alejandro Estrada García (Mexico), Jorge Galicia Carreón (Mexico), Erika Ramirez (Mexico), Mima Toledo (Mexico), Sergio Estrada Parra (Mexico), Mayra Pérez Tapia (Mexico) and María Del Carmen Jiménez Martínez (Mexico)

WAO Abstract Award
Scientific Program

Friday, 13 December 2013 — continued

**13:30 - 15:00 Biologics Track 2**

**NOVEL ANTI-CYTOKINES**

Chairpersons:
Stephen T. Holgate (United Kingdom)
Francesca Levi-Schaffer (Israel)

Learning Objectives:
- Identify the potential Anti-Cytokine and Cytokine therapy in the treatment of allergic disease.
- Describe Cytokine families involved in allergic inflammation and potential treatment based on that finding.
- Recognize Anti-Cytokine therapies that interrupt Th2 mediated allergic reactions.

13:30 - 13:35 Welcoming Remarks

13:35 - 13:55 1-13 IL-1 and IL-17 Cytokine Families: New Targets for Allergy Related Disorders | Lanny J. Rosenwasser (United States)
Learning Objectives:
- Identify anti-inflammatory affects of Anti-Cytokines directed to IL-1 and IL-17 which are active in asthma and other allergy related disorders.
- Describe the agents that will interrupt IL-1 and IL-17 mediated reactions.
- List the potential allergic disorders that are more responsive to IL-1 and IL-17 inhibition.

13:55 - 14:15 1-14 Anti-IL-5 in Asthma and Beyond | Parameswaran Nair (Canada)
Learning Objectives:
- Identify the role of Anti-IL-5 and eosinophil inhibition in asthma.
- Indicate the role of Anti-IL-5 in treating other allergic disorders.
- Explain the role of Anti-IL-5 in sparing steroid treatment in allergic disorders.

14:15 - 14:35 1-15 Anti-IL-13 Prospects in Asthma | Sally Wenzel (United States)
Learning Objectives:
- Illustrate the ability of Anti-IL-13 to inhibit Th2 mediated allergic reactions in asthma.
- Outline the effect of Anti-IL-13 on structural aspects of lung function.
- Identify which patients who receive Anti-IL-13 are more likely to make a positive response to the treatment.

14:35 - 15:00 Discussion

**13:30 - 15:00 Immunotherapy Track 2**

**SUBLINGUAL IMMUNOTHERAPY**

Chairpersons:
Sandra Gonzalez-Diaz (Mexico)
Dana Wallace (United States)

Learning Objectives:
- Define the recommendations and the procedure for allergen immunotherapy (AIT) clinical trials including the CONSORT statements and the primary outcomes to be used.
- State and discuss the successful trials of sublingual immunotherapy (SLIT) between the United States and Europe.
- Summarize the WAO SLIT Position Paper.

13:30 - 13:35 Welcoming Remarks

13:35 - 13:55 1-16 Recommendations for Appropriate Sublingual Immunotherapy Clinical Trials | Giovanni Passalacqua (Italy)
Learning Objective:
- Discuss the recommendations and the procedure for allergen immunotherapy (AIT) clinical trials including the CONSORT statements and the primary outcomes to be used.

13:55 - 14:15 1-17 Current Status of Sublingual Immunotherapy in the United States | Michael Blaiss (United States)
Learning Objective:
- State and discuss the successful trials of sublingual immunotherapy (SLIT) in both the United States and Europe.

14:15 - 14:35 1-18 WAO Position Paper Update on Sublingual Immunotherapy | G. Walter Canonica (Italy)
Learning Objectives:
- Analyze data of new SLIT global trials.
- Summarize the WAO SLIT Position Paper.
- Evaluate the new aspects of SLIT, such as new schedules.
- Discuss the safety grading system.

14:35 - 15:00 Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 – 15:30</td>
<td>Coffee Break</td>
<td>Michigan Ballroom</td>
</tr>
<tr>
<td>15:30 – 17:00</td>
<td>Biologics Track 3</td>
<td>Great Lakes Grand Ballroom East</td>
</tr>
<tr>
<td>15:00 – 17:00</td>
<td>Immunotherapy Track 3</td>
<td>Great Lakes Grand Ballroom West</td>
</tr>
</tbody>
</table>

**NEW DIRECTIONS IN IMMUNOTHERAPY**

**Chairpersons:**
- Luis Caraballo (Colombia)
- Luo Zhang (China)

**Learning Objectives:**
- Identify the potential therapeutic benefit of T Cell epitopes in allergy.
- Determine other routes of immunotherapy beyond subcutaneous injection or sublingual immunotherapy.
- Recognize alternative and new routes of administration of immunotherapy for enhanced efficacy and safety.

**15:30 - 15:35** Welcoming Remarks

**15:35 - 15:55** 1-22 Identification of Therapeutic Epitopes from Allergens | Alessandro Sette (United States)

**Learning Objectives:**
- Identify the structures within allergens that interact with IgE and T cells for allergen reactivity.
- Illustrate the use of T Cell epitopes for newer approaches to allergen immunotherapy.
- Discuss alternative and new routes of administration of immunotherapy for enhanced efficacy and safety.

**15:55 - 16:15** 1-23 Specific Immunoregulatory Epitopes in the Treatment of Allergic Disease | Mark Larché (Canada)

**Learning Objectives:**
- List the regions of allergens likely to be involved in T Cell recognition of allergens.
- Explain the potential therapeutic benefit of T Cell epitopes in allergy.
- Illustrate the increased safety of a T Cell vaccine approach.

**16:15 - 16:35** 1-24 New Routes for Allergen Immunotherapy | Thomas Kündig (Switzerland)

**Learning Objectives:**
- List other routes of immunotherapy beyond subcutaneous injection or sublingual immunotherapy.
- Analyze potential unique possibilities for intervention and allergic disease.
- Examine the practicality of new and radical approaches to immunotherapy.

**16:35 - 17:00** Discussion

**IMMUNOTHERAPY TARGETS FOR FOOD**

**Chairpersons:**
- Alessandro Fiocchi (Vatican City)
- Elham Hossny (Egypt)

**Learning Objectives:**
- Explain the importance of allergen specific components and the role of molecular based allergy in diagnosis.
- Describe the basic immunologic changes associated with epicutaneous immunotherapy (EPIT) and compare with oral and sublingual immunotherapy.

**15:30 - 15:35** Welcoming Remarks

**15:35 - 15:55** 1-19 Use of Allergen Components: A New Era in Allergology | Motohiro Ebisawa (Japan)

**Learning Objectives:**
- Assess the difference between crude extracts and allergen components.
- State the cross allergen reactive components and allergen specific components.
- Practically apply components resolved diagnosis in clinical practice.

**15:55 - 16:15** 1-20 Oral and Sublingual Immunotherapy for Food Allergy | Wesley Burks (United States)

**Learning Objectives:**
- State the types of immunotherapy being studied for food allergy.
- Explain the mechanisms identified for oral immunotherapy for food allergy.
- Describe the side effects of oral and sublingual immunotherapy for food allergy.

**16:15 - 16:35** 1-21 Epicutaneous Immunotherapy for Food Allergy | Hugh Sampson (United States)

**Learning Objectives:**
- Describe the basic immunologic changes associated with epicutaneous immunotherapy (EPIT).
- Analyze immunologic parameters indicative of successful immunotherapy.
- Compare and contrast Epicutaneous Immunotherapy (EPIT) to Oral Immunotherapy (OIT) and Sublingual Immunotherapy (SLIT).

**16:35 - 17:00** Discussion
Discover BioMed Central’s open access Allergy Journals

- Unrestricted access ensures wide dissemination of articles
- Top society affiliations: EAACI, CSACI and WAO
- Open access complies with funders’ mandates such as NIH and Wellcome Trust

Submit your manuscript today at www.biomedcentral.com
Saturday, 14 December 2013

08:00 - 09:30  Biologics Track 4  Great Lakes Grand Ballroom East

CRITICAL NOVEL MOLECULES FOR ALLERGIC DISEASES

Chairpersons:
Hirohisa Saito (Japan)
Tatiana Slavyanskaya (Russia)

Learning Objectives:
- Analyze how the discovery of novel cytokines and their receptors, which deviate the innate and adaptive immune responses, can be utilized to generate novel biologic therapeutics.
- Describe the steps required to take a novel therapeutic target through to treatment.

08:00 - 08:05  Welcoming Remarks
08:05 - 08:25  2-1 Role of Thymic Stromal Lymphopoietin (TSLP) in Allergic Responses  | Atsushi Kato (United States)
Learning Objectives:
- Support the importance of TSLP in directing the dendritic cell response towards a pro-allergic type.
- Discuss the wider opportunities for blocking this target.
- Describe the indications in which this target may deliver a stratified approach to complex allergy.

08:25 - 08:45  2-2 Role of IL-33 in Innate-Type Immune Cells in Allergy  | Susumu Nakae (Japan)
Learning Objectives:
- Summarize the origins and role of IL-33 in connecting innate and adaptive immunity in allergic disease.
- Evaluate the molecular consequences of stimulating this pathway.
- Review the novel therapeutics that are directed to this molecule and its receptor.

08:45 - 09:05  2-3 Advances in Synthetic Peptide Immuno-Regulatory Epitopes  | Peter Creticos (United States)
Learning Objective:
- Review how this novel cytokine was discovered in macrophages and epithelial cells and its link to suppression of chronic inflammation and how its actions can be harnessed for attenuating inflammatory diseases.

09:05 - 09:30  Discussion

08:00 - 09:30  Immunotherapy Track 4  Great Lakes Grand Ballroom West

OTHER NOVEL APPROACHES TO IMMUNOTHERAPY

Chairpersons:
Juan Carlos Ivancevich (Argentina)
Richard F. Lockey (United States)

Learning Objectives:
- Identify protective antibodies for allergy treatment.
- Characterize use of recombinant allergens for the diagnosis and treatment of vespid allergy.

08:00 - 08:05  Welcoming Remarks
08:05 - 08:25  2-4 Intralymphatic Immunotherapy  | Gabriela Senti (Switzerland)
Learning Objective:
- Illustrate how Intralymphatic Immunotherapy is a safe and effective alternative route in Allergen Specific Immunotherapy for the treatment of pollen induced allergic rhinoconjunctivitis.

08:25 - 08:45  2-5 Recombinant Allergens: The Present and the Future  | Rudolf Valenta (Austria)
Learning Objectives:
- Identify recombinant allergens for diagnosis.
- Discuss use of recombinant allergens for treatment of vespid allergy.

08:45 - 09:05  2-6 Passive Immunization with Allergen-Specific IgG Antibodies for the Treatment and Prevention of Allergy  | Rudolf Valenta (Austria)
Learning Objectives:
- Identify passive IgG for treatment of allergy.
- Cite protective antibodies for allergy treatment.

09:05 - 09:30  Discussion

ENHANCE YOUR LEARNING EXPERIENCE!
Use the number to the left-side of the talk title to view handouts on the Handout USB Example: 1-1.
### BIOMARKERS, BIOSIMILARS AND SELECTION OF PATIENTS

**Chairpersons:**
- Stanley Fineman (United States)
- Alessandro Fiocchi (Vatican City)

**Learning Objectives:**
- Identify biomarkers that differentiate specific subtypes of allergic disease.
- Describe how biomarkers are developed into diagnostic tests.
- Illustrate how an antibody target can be transformed into a target for small chemical entities that do the same thing as the antibody.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:05</td>
<td>Welcoming Remarks</td>
<td></td>
<td>Michigan Ballroom</td>
</tr>
<tr>
<td>10:05 - 10:25</td>
<td>2-7 The Use of Biomarkers in Asthma Clinical Research Trials</td>
<td>Robert Lemanske (United States)</td>
<td>Great Lakes Grand Ballroom East</td>
</tr>
<tr>
<td>10:25 - 10:45</td>
<td>2-8 Inner City Asthma and Anti-IgE</td>
<td>William Busse (United States)</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:05</td>
<td>2-9 Biosimilars</td>
<td>Sergio Bonini (Italy)</td>
<td></td>
</tr>
<tr>
<td>11:05 - 11:30</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SOCIAL CONSEQUENCES AND EVIDENCE BASED MEDICINE AND IMMUNOTHERAPY

**Chairpersons:**
- Linda Cox (United States)
- Giovanni Passalacqua (Italy)

**Learning Objectives:**
- Identify the standardization of analysis of immunotherapy trials.
- Explain the analysis of inhalant allergen immunotherapy trials utilizing standardized criteria.
- Identify stratification of patients by allergen sensitization as well as by therapeutic response.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:05</td>
<td>Welcoming Remarks</td>
<td></td>
<td>Michigan Ballroom</td>
</tr>
<tr>
<td>10:05 - 10:25</td>
<td>2-10 The Consolidated Standards of Reporting Trials (CONSORT) Statement Applied to Allergen-Specific Immunotherapy with Inhalant Allergens</td>
<td>Jan Brozek (Canada)</td>
<td>Great Lakes Grand Ballroom West</td>
</tr>
<tr>
<td>10:25 - 10:45</td>
<td>2-11 Pharmacoeconomics of Immunotherapy</td>
<td>Cheryl Hankin (United States)</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:05</td>
<td>2-12 Selection of Patients for Sublingual versus Subcutaneous Immunotherapy</td>
<td>Désirée Larenas-Linnewald (Mexico)</td>
<td></td>
</tr>
<tr>
<td>11:05 - 11:30</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Saturday, 14 December 2013 — continued

11:30 – 12:00  Lunch Break

12:00 – 13:00  Poster Session 2  Michigan Ballroom

Chairpersons:
João Tebyriça (Brazil)
Ruchi Gupta (United States)

2000  A Case Study in Effective Innovative Strategic Multi-modal Recruitment Strategies in Difficult-to-Recruit Patient Populations: Study of Safety and Tolerability of Novel SLIT in an Adolescent Population | Anne Marie Salapatek (Canada), Justin Buck (Canada) and Piyush Patel (Canada)

2001  Generation a hypoallergenic profilin from Amanthus palmeri pollen | Cesar Manuel Landa (Mexico), and César Augusto Sandino Reyes (Mexico)

2002  Transfer Factor May Provide Immunomodulation In Cutaneous Tuberculosis | Laura Vidal (Mexico) and Damian Palafox (Mexico)

2003  Cat-PAD, The First In a New Class Of Synthetic Peptide Immuno-Regulatory Epitopes, Demonstrates a Favourable Safety and Tolerability Profile In Patients With Cat–Induced Rhinoconjunctivitis | Roderick Peter Hafner (United Kingdom) and John Powell (United Kingdom)

2004  Bio Immun(G)En Medicine Or How To Link Scientific Research and Daily Therapeutic Practice | Gilbert Glad (France)

2005  Application Of a Standardized Titrated Nasal Provocation Test With HDM and Birch Pollen Extract In Multicentre Clinical Studies In Allergic Rhinitis | Didrik Boot (Netherlands), Oliver Pfaar (Germany), Zuzana Diamant (Sweden) and Claus Bachert (Belgium)

2006  Fel d 1 Derived Synthetic Peptide Immune–Regulatory Epitopes Improve Nasal Symptoms Of Cat Allergy 2 Years After Administration Of 4 Doses Over a 12 Week Period | Roderick Peter Hafner (United Kingdom), Peter Couroux (Canada), Kristen Armstrong (Canada), Deepen Patel (Canada) and Mark Larché (Canada)

2007  Treatment With Fel d 1 Derived Synthetic Peptide Immune–Regulatory Epitopes Results In a Persistent Treatment Effect On Symptoms Of Cat Allergy 2 Years After Treatment With 4 Doses 4 Weeks Apart | Roderick Peter Hafner (United Kingdom), Peter Couroux (Canada), Kristen Armstrong (Canada), Deepen Patel (Canada) and Mark Larché (Canada)

2008  Sublingual RUSH Immunotherapy | Ramandra Nath Mitra (India), Kaushik Chakraborty (India) and Naren Pandey (India)

2009  Clinical Substantiation Of Immunocorrective Therapy In Children With Atopic Dermatitis | Tatiana Slavynskaya (Russia) and Vasilis derkach (Russia)

2010  A Study Assessing The Safety and Efficacy Of Subcutaneous Immunotherapy With a Dust Mite Vaccine With The Adjuvant L-Tyrosine In a Highly Sensitized Population In a Latin-American City | Ricardo Cardona Villa (Colombia), Carlos Fernando Chinchilla Mejia (Colombia), Ruth Helena Ramirez Giraldo (Colombia), Maria Margarita Olivares Gomez (Colombia), Victor Calvo (Colombia) and Jorge F Maspero (Argentina)

2011  A DNA Vaccine Immunotherapy For Japanese Red Cedar Allergy | Lawrence Weiner (United States), Bruce Mackler (United States), Bill Heal (United States) and David Fitz-Patrick (United States)

2012  House Dust Mite Sublingual Immunotherapy With Standardized Vaccines: Prescription and Adverse Events | Alexander Diaz Rodriguez (Cuba)

2013  The Safety Of The United Allergy Services Immunotherapy Protocol | Frederick Schaffer (United States), Andrew Napes (United States), Myla Ebeling (United States), Thomas Eble (United States) and Larry Garner (United States)

2014  A Survey Of Respiratory Physicians’ Opinion Of SIT In Asthma Treatment In Wuhan Of China | Rongfei Zhu (China), Nan Huang (China) and Guanghui Liu (China)

2015  Quality Of Life Improvement With Sublingual Immunotherapy: A Prospective Study Of Efficacy | Mary S. Morris (United States), Amanda Lowery (United States), Demetrios Theodoropoulos (United States), R. Daniel Duquette (United States) and David L. Morris (United States)

2016  The Effect and Value Of Sublingual Immunotherapy: A Patient Survey | Mary S. Morris (United States), Emma Killoran (United States), Jeffrey Kessler (United States), Moira Killoran (United States) and Amanda Lowery (United States)

2017  Molecular Profiles Of IgE To Timothy Grass Allergens In Patients Screened For Grass Tablet Immunotherapy | Maria Nolte (United States), Jennifer Maloney (United States) and Hendrik Nolte (United States)

WAO Abstract Award
Scientific Program

Saturday, 14 December 2013 — continued

2018 Efficacy and Safety Of Grass Sublingual Immunotherapy Tablet (SLIT-T) Treatment In a Large Randomized Controlled Trial In North American Children and Adults | Hendrik Nolte (United States), Jennifer Maloney (United States), David Bernstein (United States), Harold Nelson (United States), Peter Creticos (United States), Jacques Hébert (Canada), Michael Noonan (United States), David Skoner (United States), Yijie Zhou (United States) and Amarjot Kaur (United States)

2019 Grass Sublingual Immunotherapy Tablet (SLIT-T) Treatment Is Associated With Similar Efficacy and Safety In Children and Adults: Subgroup Analysis Of Data From a Large North American Trial | Hendrik Nolte (United States), David Bernstein (United States), Harold Nelson (United States), Amarjot Kaur (United States) and Jennifer Maloney (United States)

2020 Effect Of Sublingual Immunotherapy Tablet (SLIT-T) Treatment On Daily Medication Score Using Alternative Scoring Methods Based On WAO Recommendations | Thomas Casale (United States), Hendrik Nolte (United States), Jennifer Maloney (United States), Amarjot Kaur (United States) and Harold Nelson (United States)

2021 The Incidence Of Adverse Reactions Induced By Subcutaneous Immunotherapy In An Allergy Center In Monterrey, México: A Retrospective Chart Review | Sandra Nora Gonzalez-Diaz (Mexico), Alfredo Arias (Mexico), Lorena Rangel (Mexico), Rafael Perez-Vanzzini (Mexico) and Samuel Palma-Gomez (Mexico)

2022 Sublingual Immunotherapy In The Treatment Of Allergic Rhinitis: Series Of Cases | Sandra Nora Gonzalez-Diaz (Mexico), Alfredo Arias-Cruz (Mexico) and Lorena Rangel (Mexico)

13:00 - 13:30 Special Lecture Great Lakes Grand Ballroom

MOLECULAR MECHANISMS AND TREATMENT OF HEREDITARY ANGIOEDEMA (HAE)

Chairperson: Allen Kaplan (United States)

Learning Objectives:
• Explain the underlying molecular mechanisms of the different types of HAE.
• Discuss novel therapeutic strategies.
• Explain the approach of laboratory diagnosis.

13:00 - 13:05 Welcoming Remarks
13:05 - 13:30 2-13 Special Lecture | Bruce Zuraw (United States)
Nota do Editor / Editor’s Note

Brazilian Journal of Allergy and Immunology: no caminho da internacionalização.

Editorial / Editorial

Alergia, obesidade, microbiota e transplante de fezes: o que isto significa para nossa saúde? Allergy, obesity, microbiota, and fecal transplantation: what do they mean to our health?

Artigos de Revisão / Review Articles


Artigos Originais / Original Articles

Associação entre o ganho de peso e a prevalência e gravidade de sibilância e asma. Association between weight gain and the prevalence and severity of wheezing and asthma. | Sensibilização a aeroalérgenos em pacientes com suspeita de alergia respiratória. Sensitization to inhaled allergens in patients with suspected respiratory allergy. | Determinação de IgE específica in vivo e in vitro após a imunoterapia específica. In vivo and in vitro specific IgE determination after specific immunotherapy. | Resposta clínica de pacientes com imunodeficiência comum variável submetidos a vacinação. Clinical evaluation of patients with common variable immunodeficiency before and after immunization. | Teste de contato atópico com aeroalérgenos na dermatite atópica. Atopy patch test with aeroallergens in atopic dermatitis.

Programa de Educação Médica Continuada / Continuing Medical Education
# Scientific Program

## Saturday, 14 December 2013 — continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 14:00</td>
<td><strong>Keynote Lecture</strong></td>
<td>Great Lakes Grand Ballroom</td>
</tr>
<tr>
<td></td>
<td><strong>PERSONALIZED/PRECISION MEDICINE: OPPORTUNITIES AND CHALLENGES</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Summarize the goals of “precision”, “personalized”, “stratified” or “P4” medicine.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Explain how efforts to achieve such “precision medicine” will influence the development of diagnostic testing, as well as drug development.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe some representative challenges to the implementation of cost-effective “precision medicine”.</td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td>2-14 **Keynote Lecture</td>
<td>Stephen J. Galli (United States)</td>
</tr>
<tr>
<td>14:00 - 14:45</td>
<td><strong>WAO Presidential Lecture</strong></td>
<td>Great Lakes Grand Ballroom</td>
</tr>
<tr>
<td></td>
<td><strong>ADVANCES IN WAO: FROM VISION TO ACTION</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairperson:</strong> Paul Greenberger (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14:00 – 14:05 Welcoming Remarks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14:05 – 14:30 WAO Presidential Lecture</td>
<td>Ruby Pawankar (Japan)</td>
</tr>
<tr>
<td></td>
<td>14:30 – 14:45 WAO Awards Presentation</td>
<td></td>
</tr>
<tr>
<td>14:45 - 15:15</td>
<td><strong>Coffee Break</strong></td>
<td>Michigan Ballroom</td>
</tr>
<tr>
<td>15:15 - 16:00</td>
<td><strong>WAO Junior Member Session</strong></td>
<td>Great Lakes Grand Ballroom</td>
</tr>
<tr>
<td></td>
<td><strong>PRACTICAL COURSE ON IMMUNOTHERAPY</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairpersons:</strong> Ignacio J. Ansotegui (Spain) Michael Blaiss (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the present and future situation of immunotherapy in Latin America.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the types of social media and other new technology that can be used to improve utilization and adherence to immunotherapy.</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:20</td>
<td>Welcoming Remarks</td>
<td></td>
</tr>
<tr>
<td>15:20 - 15:35</td>
<td>2-16 **Current Status and Future Perspectives of Immunotherapy in Latin America and Cuba</td>
<td>Great Lakes Grand Ballroom</td>
</tr>
<tr>
<td></td>
<td>Alexander Diaz Rodriguez (Cuba)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the present situation and future perspective of immunotherapy in Latin America.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the current conditions and projections of immunotherapy in Cuba.</td>
<td></td>
</tr>
<tr>
<td>15:35 - 15:50</td>
<td>2-17 **Use of New Technology to Improve Utilization and Adherence to Immunotherapy</td>
<td>Great Lakes Grand Ballroom</td>
</tr>
<tr>
<td></td>
<td>Ves Dimov (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the types of social media and other new technology that can be used to improve utilization and adherence to immunotherapy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Create awareness of recommended approaches to the use of social media in allergy and immunology.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify the new developments that aim to improve utilization and adherence to immunotherapy.</td>
<td></td>
</tr>
<tr>
<td>15:50 – 16:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td><strong>WAO &amp; AAAAI Session</strong></td>
<td>Great Lakes Grand Ballroom</td>
</tr>
</tbody>
</table>

---

**ENHANCE YOUR LEARNING EXPERIENCE!**

Use the number to the left-side of the talk title to view handouts on the Handout USB. Example: 1-1.
UPDATE ON URTICARIA GUIDELINES

Chairpersons:
Michael Blaiss (United States)
Ignacio J. Ansotegui (Spain)

16:00 - 16:05  Welcoming Remarks
16:05 - 16:25  2-18 Overview of Acute and Chronic Urticaria | Bruce Zuraw (United States)
   Learning Objectives:
   • Contrast the differences between acute and chronic urticaria.
   • Discuss the overlap and differences between urticaria and angioedema.
   • Review the diagnostic features and evaluation of acute and chronic urticaria.

16:25 – 16:45  2-19 Chronic Urticaria: New Management Options | Paul A. Greenberger (United States)
   Learning Objectives:
   • Describe the guideline-driven therapy for chronic urticaria.
   • Discuss the rationale and efficacy of omalizumab and other alternative therapies for chronic urticaria.
   • Apply evidence-based recommendations accurately for the management of chronic urticaria in simulated patient encounters.

16:45 – 17:00  Discussion
Biology and Chemistry of Beta Glucan
Beta-glucan, Structure, Chemistry and Specific Application

www.benthamscience.com/ebooks/9781608053018

About the ebook
This volume presents modern chemical and separation methods which are applied in structural analysis of glucans. The book further discusses the biological effects of tailored oligomers and synthetic beta-glucans, including innovative use of enzymatic processes in the synthesis of these compounds. This volume also discusses a hypothesis of beta-glucans’ increasing impact on the photodynamic therapy and aquaculture.

Contents

- Structural Analysis of Fungal Glucans
- Insights into the Physicochemical Characterization, Chemistry, Structure and Synthesis of (1 → 3,1 → 6)- β-Glucans
- Chemical Synthesis of Oligo-(1→3)-β-D-Glucans
- Contribution of Biocatalysis to the Synthesis of β-(1,3)-Glucans
- Modulation of Photodynamic Therapy by β-Glucan
- Human Exposures to β-Glucan in the Environment

For Sales and Advertising Inquiries: Contact: marketing@benthamscience.org

Visit: www.benthamscience.com/ebooks
or email: ebooks@benthamscience.org for more information
The Exhibit Hall is located in the Michigan Ballroom and is open during the following dates and times:

- 13 December 2013: 09:30 – 15:30
- 14 December 2013: 09:30 – 15:30

**Ora, Inc.**

300 Brickstone Square  
Andover, MA  
United States 01810  
Telephone: +1 978-685-899  
Fax: +1 978-689-0020  
Website: www.oraclinical.com

Ora is the world’s leading independent, full-service allergy CRO and product development firm. Over the past 30 years, we helped our clients earn 34 FDA approvals. We support a wide array of organizations, from start-ups to global device and pharmaceutical companies, to efficiently and successfully bring their new products from concept to market. Ora’s clinical models and unique methodologies, including The Boston Chamber and Nasal and Conjunctival Allergen Challenges, and regulatory strategies have been refined across thousands of projects both in the US and internationally. We bring together an extensive and experienced network of allergy experts to maximize the value of new product initiatives.

**Sanofi**

55 Corporate Drive  
Bridgewater, New Jersey  
United States 08807  
Telephone: +1 800-981-2491  
Website: www.sanofi.us or www.sanofi.com (Global)

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

**ViroPharma**

730 Stockton Dr  
Downingtown, PA  
United States 19335  
Telephone: +1 610-458-7300  
Website: www.viropharma.com

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich’s Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. In the United States and Canada, we focus our commercial efforts on a product for prevention of attacks of hereditary angioedema (HAE). In Europe, we are commercializing products for hereditary angioedema, adrenal insufficiency (AI) and prolonged, acute, convulsive seizures in children and adolescents.
Save the Date!

PRELIMINARY AGENDA

2014 CIS Annual Meeting: Primary Immune Deficiency Diseases North American Conference
APRIL 10 – 13, 2014 • BALTIMORE, MD

THURSDAY, APRIL 10
8:00am – 5:30pm  School on Diagnostic Assessment of immune Phenotyping and Function in PIDs
6:00pm – 7:00pm  Robert A. Good Lecture: Opening Lecture
7:00pm – 8:30pm  Opening Reception

FRIDAY, APRIL 11
7:00am – 8:00am  Breakfast
7:30am – 8:00am  Guided Poster Session
8:00am – 10:00am  Plenary: The Colonizers and Us
10:00am – 10:30 am  Morning Break
10:30am – 11:30 am  Tales from the Listserv
11:30am – 1:00pm  Lunch / Poster Viewing / Exhibit Hall Open
11:30am – 1:00pm  Alumni PID School Luncheon & Photo
1:00pm – 3:00pm  Plenary: Infectious Manifestations of PID Around the World
3:00pm – 3:30pm  Afternoon Break
3:30pm – 5:00pm  Concurrent Workshops
Session 1: Malignancy in PIDO
Session 2: Bugs and Drugs
Session 3: Immunoglobulin Replacement Therapy
5:15pm – 6:15pm  The CIS Fahey/Rose Founders Lecture

SATURDAY, APRIL 12
7:30am – 9:00am  Concurrent Breakfast Sessions
Session 1: Immune Globulin
Session 2: Targeted Manipulation of the Genome
9:00am – 9:30am  CIS Business Meeting
9:30am – 10:00am  Morning Break
9:30am – 10:00am  Guided Poster Sessions
10:00am – 12:00pm  Plenary: Transplantation
12:00pm – 1:30pm  Lunch / Poster Viewing / Exhibit Hall Open
1:30pm – 3:00pm  Plenary Session: Hot New Defects
3:00pm – 3:30pm  Afternoon Break
3:30pm – 5:30pm  Plenary: Innate Lymphoid Cells
5:30pm – 6:00pm  Presidential Award Presentation & Lecture
6:00pm – 7:30pm  CIS Post Presidents Reception

SUNDAY, APRIL 13
8:00am – 9:30am  Concurrent Breakfast Sessions
Session 1: Proactive Surveillance
Session 2: Genetic Testing
9:30am – 9:45am  Morning Break
9:45am – 11:45am  Plenary: Targeted Therapies

Visit www.clinimmsoc.org/am2014 for more information
Collaborating Partners

WAO would like to thank the following collaborating partner for their generous support of the 2013 WAO Symposium on Immunotherapy and Biologics:

![American Academy of Allergy Asthma & Immunology](image)

Media Partners

Thank you to all of our Media Partners for their generous support in helping to raise awareness of the 2013 WAO Symposium on Immunotherapy and Biologics in Chicago, IL, United States. With your support we are able to increase awareness of WAO’s mission to be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training.

![AAIR Allergy, Asthma & Immunology Research](image)
![BioMed Central](image)
![International Archives of Allergy and Immunology](image)
![Journal of Investigational Allergology and Clinical Immunology](image)
![Bentham Science](image)
![The World Allergy Organization Journal](image)
Food Allergy

Editors
M. Ebisawa
B. Ballmer-Weber
S. Vieths
R.A. Wood

Tentative Contents

General Aspects
- Historical background, definitions and differential diagnosis: Sampson, H.A.
- Immunological basis of food allergy: Burks, W.A.; Kim, E.
- Food allergens: Molecular and immunological aspects, cross reactivity, allergen database: Vieths, S.; Scheurer, S.

Clinical Aspects
- Food allergy in childhood: Eigenmann, P.; Bergmann, M.
- Food allergy in adolescence and adulthood: Ballmer-Weber, B.

Diagnosis and Management
- Food Allergy: Hints for the diagnosis: Poulsen, L.
- IgE-related diagnostic methods (Ag-specific IgE, CRD, SPT, HRT, CD209(c2).
- Non-IgE-related diagnostic methods (I.ST, patch test): Matsumoto, K.
- Diagnostic elimination diets and oral food provocations: Wood, R.A.
- Pharmacological treatment for acute food allergic reactions: Tang, M.
- Oral immunotherapy and other potential treatments: Sato, S.; Yanagida, N.; Ebisawa, M.

Allergen-Based Food Allergies
- Cow’s milk allergy: Fiocchi, A.
- Hen’s egg allergy: Utsu, A.; Kondo, Y.; Tsuge, I.
- Peanut and tree nut allergy: Sichteris, S.; Cox, A.
- Grain and legume allergy: Ito, K.
- Fish and shellfish allergy: Lee, B.-W.
- Fruit and vegetable allergy: Fernández-Rivas, M.

Disease-Based Food Allergies
- Food-induced gastrointestinal disorders: Heine, R.
- Atopic eczema and food allergy: Werfel, T.; Weissmann, A.
- Anaphylaxis in food allergy: Jones, S.M.; Pesek, R.
- Eosinophilic esophagitis: Allen, K.; Heine, R.

Special Topics
- Nutritional aspects and diets: Nowak-Wegrzyn, A.
- Social countermeasures and psychological aspects: Sharma, H.P.; Herbert, L.
- Food allergy labeling worldwide and detection of allergens in processed foods: Taylor, S.; Baumert, J.
- Quality of life: Dunn Galvin, A.
- Prevention of food allergy: Du Toit, G.
- Educational programs in food allergy: Ring, J.; Kugler, C.

Order Form

Food Allergy
Editors: Ebisawa, M. (Sapporo); Ballmer-Weber, B. (Zürich); Vieths, S. (Langen); Wood, R.A. (Baltimore, Md.)
Approx. 200 p., hardcover, 2014
Appearing: 1st quarter 2014
Special prepublication price: CHF 96.00 / EUR 80.00 / USD 113.00
Prices subject to change:
EUR price for Germany.
US$ price for USA and Latin America only
ISBN: 978-3-18-02394-4

Chemical Immunology and Allergy,
Vol. 101
Series Editors: Ring, J. (Munich); Bocquet, K. (Davos); Capron, M. (Lille); Dammann, J.A. (Hamilton); Helgat, S.T. (Southampton); Marone, G. (Naples); Sato, H. (Tokyo)
ISSN: 1660-1642

www.karger.com

Please send: _______ copies

Payment:
- Please charge to my credit card
- American Express □ Diners □ MasterCard □ Visa

Card No.:
Exp. date:
CVV2/CVC
(Signature)
Check enclosed □ Please bill me

Date:
Signature:
Go Global with the WAO Junior Members Group
JOIN TODAY!
www.worldallergy.org/juniormembers

Help shape the future of WAO through global advocacy and leadership as a Junior Member

Who Qualifies to Be a WAO Junior Member?
- Working in the field of allergy/clinical immunology
- Under 35 years of age or within 5 years of a training program in allergy, asthma, clinical immunology or related field
- A current member of a WAO Member Society

The WAO Junior Members Group is a network of young allergists/clinical immunologists and scientists who interact with WAO to identify the key issues affecting the world's up-and-coming allergy practitioners and to advise on ways to help meet their educational and training needs.

WAO Junior Members Group

What benefits will you enjoy as a WAO Junior Member?
- Travel grants to WAO educational activities, including the World Allergy Congress
- A worldwide professional network of junior physicians and scientists
- Occasions to interact with the leading international experts in the field
- The opportunity to develop a leadership role in the specialty
- Junior Member rates for WAO scientific meetings
- Dedicated activities and educational sessions for Junior Members at WAO scientific meetings
- Opportunities for publication of research in the World Allergy Organization Journal
- An online destination for Junior Member news and networking
- A column in the WAO News and Notes electronic newsletter written by and for Junior Members

For more information or to apply for membership, please visit or contact us: www.worldallergy.org/juniormembers at info@worldallergy.org

Follow us on: facebook twitter

WORLD ALLERGY ORGANIZATION
A World Federation of Allergy, Asthma & Clinical Immunology Societies
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Handout/Abstract Number</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akdis, Cezmi</td>
<td>Speaker</td>
<td>1-3</td>
<td>13</td>
</tr>
<tr>
<td>Akdis, Mübeccel</td>
<td>Speaker</td>
<td>1-4</td>
<td>13</td>
</tr>
<tr>
<td>Ansotegui, Ignacio J.</td>
<td>Chairperson</td>
<td></td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td></td>
<td>28</td>
</tr>
<tr>
<td>Bachert, Claus</td>
<td>Chairperson</td>
<td>14</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>1003</td>
<td>17</td>
</tr>
<tr>
<td>Benjaponpitak, Suwat</td>
<td>Chairperson</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Berings, Margot</td>
<td>Poster Presenter</td>
<td>1021</td>
<td>18</td>
</tr>
<tr>
<td>Blaiss, Michael</td>
<td>Speaker</td>
<td>1-17</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td></td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td></td>
<td>28</td>
</tr>
<tr>
<td>Bochner, Bruce S.</td>
<td>Speaker</td>
<td>1-2</td>
<td>13</td>
</tr>
<tr>
<td>Bonini, Sergio</td>
<td>Speaker</td>
<td>2-9</td>
<td>23</td>
</tr>
<tr>
<td>Boot, Diderik</td>
<td>Poster Presenter</td>
<td>2005</td>
<td>24</td>
</tr>
<tr>
<td>Brozek, Jan</td>
<td>Speaker</td>
<td>2-10</td>
<td>23</td>
</tr>
<tr>
<td>Burks, Wesley</td>
<td>Speaker</td>
<td>1-20</td>
<td>20</td>
</tr>
<tr>
<td>Busse, William</td>
<td>Speaker</td>
<td>2-8</td>
<td>23</td>
</tr>
<tr>
<td>Canonica, G. Walter</td>
<td>Speaker</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>1001</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>1002</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Speaker</td>
<td>1-18</td>
<td>19</td>
</tr>
<tr>
<td>Caraballo, Luis</td>
<td>Chairperson</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Chen, Hua</td>
<td>Poster Presenter</td>
<td>1024</td>
<td>18</td>
</tr>
<tr>
<td>Colfman, Robert</td>
<td>Poster Presenter</td>
<td>1019</td>
<td>18</td>
</tr>
<tr>
<td>Compalati, Enrico</td>
<td>Poster Presenter</td>
<td>1000</td>
<td>17</td>
</tr>
<tr>
<td>Costa, Ana Célia</td>
<td>Poster Presenter</td>
<td>1012</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>1020</td>
<td>18</td>
</tr>
<tr>
<td>Cox, Linda</td>
<td>Speaker</td>
<td>1-11</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td></td>
<td>23</td>
</tr>
<tr>
<td>Creticos, Peter</td>
<td>Speaker</td>
<td>2-3</td>
<td>22</td>
</tr>
<tr>
<td>Diaz Rodriguez, Pablo</td>
<td>Poster Presenter</td>
<td>2012</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Speaker</td>
<td>2-16</td>
<td>27</td>
</tr>
<tr>
<td>Dimov, Ves</td>
<td>Speaker</td>
<td>2-17</td>
<td>27</td>
</tr>
<tr>
<td>Ebisawa, Motohiro</td>
<td>Speaker</td>
<td>1-19</td>
<td>20</td>
</tr>
<tr>
<td>Fineman, Stanley</td>
<td>Chairperson</td>
<td></td>
<td>23</td>
</tr>
<tr>
<td>Fiocchi, Alessandro</td>
<td>Chairperson</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td></td>
<td>23</td>
</tr>
<tr>
<td>Fogg, Michael</td>
<td>Chairperson</td>
<td></td>
<td>17</td>
</tr>
<tr>
<td>Galicia Carreón, Jorge</td>
<td>Poster Presenter</td>
<td>1026</td>
<td>18</td>
</tr>
<tr>
<td>Galli, Stephen J.</td>
<td>Speaker</td>
<td>2-14</td>
<td>27</td>
</tr>
<tr>
<td>Ghazi, Farideh</td>
<td>Poster Presenter</td>
<td>1015</td>
<td>17</td>
</tr>
<tr>
<td>Glad, Gilbert</td>
<td>Poster Presenter</td>
<td>2004</td>
<td>24</td>
</tr>
<tr>
<td>Gonzalez-Diaz, Sandra</td>
<td>Chairperson</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Greenberger, Paul A.</td>
<td>Chairperson</td>
<td></td>
<td>27</td>
</tr>
<tr>
<td>Gupta, Ruchi</td>
<td>Chairperson</td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Hafner, Roderick Peter</td>
<td>Poster Presenter</td>
<td>2003</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>2006</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>2007</td>
<td>24</td>
</tr>
<tr>
<td>Hankin, Cheryl</td>
<td>Speaker</td>
<td>2-11</td>
<td>23</td>
</tr>
<tr>
<td>Haruna, Takenori</td>
<td>Poster Presenter</td>
<td>1005</td>
<td>17</td>
</tr>
<tr>
<td>Hohti, Jens M.</td>
<td>Poster Presenter</td>
<td>1007</td>
<td>17</td>
</tr>
<tr>
<td>Holgate, Stephen T.</td>
<td>Speaker</td>
<td>1-6</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Homberg, Toni Angela</td>
<td>Poster Presenter</td>
<td>1008</td>
<td>17</td>
</tr>
<tr>
<td>Hossny, Elham</td>
<td>Chairperson</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Israel, Elliot</td>
<td>Speaker</td>
<td>1-1</td>
<td>13</td>
</tr>
<tr>
<td>Ivancevich, Juan Carlos</td>
<td>Chairperson</td>
<td></td>
<td>22</td>
</tr>
<tr>
<td>Kaplan, Allen</td>
<td>Chairperson</td>
<td></td>
<td>25</td>
</tr>
<tr>
<td>Kato, Atsushi</td>
<td>Speaker</td>
<td>2-1</td>
<td>22</td>
</tr>
<tr>
<td>Kelly, Ludmila</td>
<td>Poster Presenter</td>
<td>1013</td>
<td>17</td>
</tr>
<tr>
<td>Khanolkar, Aaruni</td>
<td>Poster Presenter</td>
<td>1018</td>
<td>17</td>
</tr>
<tr>
<td>Kündig, Thomas</td>
<td>Speaker</td>
<td>1-24</td>
<td>20</td>
</tr>
<tr>
<td>Landa, Cesar Manuel</td>
<td>Poster Presenter</td>
<td>2001</td>
<td>24</td>
</tr>
<tr>
<td>Larché, Mark</td>
<td>Speaker</td>
<td>1-23</td>
<td>20</td>
</tr>
<tr>
<td>Larenas-Linermann, Désirée</td>
<td>Poster Presenter</td>
<td>1009</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>1010</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Speaker</td>
<td>2-12</td>
<td>23</td>
</tr>
<tr>
<td>Lee, Jun Sik</td>
<td>Poster Presenter</td>
<td>1004</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>1006</td>
<td>17</td>
</tr>
<tr>
<td>Lemanske, Robert</td>
<td>Speaker</td>
<td>2-7</td>
<td>23</td>
</tr>
<tr>
<td>Levi-Schaffer, Francesca</td>
<td>Chairperson</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Lieberman, Phil</td>
<td>Speaker</td>
<td>1-12</td>
<td>15</td>
</tr>
<tr>
<td>Lockey, Richard F.</td>
<td>Speaker</td>
<td>1-9</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td></td>
<td>22</td>
</tr>
<tr>
<td>Maspero, Jorge F</td>
<td>Poster Presenter</td>
<td>2010</td>
<td>24</td>
</tr>
<tr>
<td>Mitra, Ramandra Nath</td>
<td>Poster Presenter</td>
<td>2008</td>
<td>24</td>
</tr>
<tr>
<td>Morris, Mary S.</td>
<td>Poster Presenter</td>
<td>2015</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>2016</td>
<td>24</td>
</tr>
<tr>
<td>Nair, Parameswaran</td>
<td>Speaker</td>
<td>1-14</td>
<td>19</td>
</tr>
<tr>
<td>Nakae, Susumu</td>
<td>Speaker</td>
<td>2-2</td>
<td>22</td>
</tr>
<tr>
<td>Nolte, Hendrik</td>
<td>Poster Presenter</td>
<td>2017</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>2018</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>2019</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>2020</td>
<td>25</td>
</tr>
<tr>
<td>Passalacqua, Giovanni</td>
<td>Speaker</td>
<td>1-16</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Chairperson</td>
<td></td>
<td>23</td>
</tr>
<tr>
<td>Pawankar, Ruby</td>
<td>Chairperson</td>
<td>1-5</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Speaker</td>
<td></td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Speaker</td>
<td></td>
<td>27</td>
</tr>
<tr>
<td>Pfaar, Oliver</td>
<td>Speaker</td>
<td>1-10</td>
<td>15</td>
</tr>
<tr>
<td>Rangel, Lorena</td>
<td>Poster Presenter</td>
<td>2021</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>2022</td>
<td>25</td>
</tr>
<tr>
<td>Rosario-Filho, Nelson</td>
<td>Chairperson</td>
<td></td>
<td>14</td>
</tr>
<tr>
<td>Rosenwasser, Lanny J.</td>
<td>Chairperson</td>
<td></td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Speaker</td>
<td>1-13</td>
<td>19</td>
</tr>
<tr>
<td>Saini, Sarbjit</td>
<td>Speaker</td>
<td>1-8</td>
<td>14</td>
</tr>
<tr>
<td>Salapatek, Anne Marie</td>
<td>Poster Presenter</td>
<td>2000</td>
<td>24</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Handout/Abstract Number</td>
<td>Page Number</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------</td>
<td>-------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Sampson, Hugh</td>
<td>Speaker</td>
<td>1-21</td>
<td>20</td>
</tr>
<tr>
<td>Sanchez Borges, Mario</td>
<td>Chairperson</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Schaffer, Frederick</td>
<td>Poster Presenter</td>
<td>2013</td>
<td>24</td>
</tr>
<tr>
<td>Senti, Gabriela</td>
<td>Speaker</td>
<td>2-4</td>
<td>22</td>
</tr>
<tr>
<td>Sette, Alessandro</td>
<td>Speaker</td>
<td>1-22</td>
<td>20</td>
</tr>
<tr>
<td>Slavyanskaya, Tatiana</td>
<td>Chairperson</td>
<td>2009</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Swanson, Brian</td>
<td>Poster Presenter</td>
<td>1023</td>
<td>18</td>
</tr>
<tr>
<td>Tebyriça, João</td>
<td>Chairperson</td>
<td></td>
<td>24</td>
</tr>
<tr>
<td>Townley, Robert</td>
<td>Poster Presenter</td>
<td>1017</td>
<td>17</td>
</tr>
<tr>
<td>Tropper, Guy</td>
<td>Poster Presenter</td>
<td>1025</td>
<td>18</td>
</tr>
<tr>
<td>Umetsu, Dale</td>
<td>Speaker</td>
<td>1-7</td>
<td>14</td>
</tr>
<tr>
<td>Valenta, Rudolf</td>
<td>Speaker</td>
<td>2-5</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Speaker</td>
<td>2-6</td>
<td>22</td>
</tr>
<tr>
<td>Van Schijndel, Hans</td>
<td>Poster Presenter</td>
<td>1016</td>
<td>17</td>
</tr>
<tr>
<td>Vidal, Laura</td>
<td>Poster Presenter</td>
<td>1011</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Poster Presenter</td>
<td>2002</td>
<td>24</td>
</tr>
<tr>
<td>Wallace, Dana</td>
<td>Chairperson</td>
<td></td>
<td>19</td>
</tr>
<tr>
<td>Weiner, Lawrence</td>
<td>Poster Presenter</td>
<td>2011</td>
<td>24</td>
</tr>
<tr>
<td>Wenzel, Sally</td>
<td>Speaker</td>
<td>1-15</td>
<td>19</td>
</tr>
<tr>
<td>Zazzali, James</td>
<td>Poster Presenter</td>
<td>1022</td>
<td>18</td>
</tr>
<tr>
<td>Zhang, Luo</td>
<td>Chairperson</td>
<td></td>
<td>20</td>
</tr>
<tr>
<td>Zhu, Rongfei</td>
<td>Poster Presenter</td>
<td>2014</td>
<td>24</td>
</tr>
<tr>
<td>Zuraw, Bruce</td>
<td>Speaker</td>
<td>2-13</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Speaker</td>
<td>2-18</td>
<td>28</td>
</tr>
</tbody>
</table>
WAO Member Societies

All Active Members of dues-paying Member Societies are Individual Members of the World Allergy Organization (WAO).

Albanian Society of Allergology and Clinical Immunology
National Association for Private Algerian Allergists
American Academy of Allergy, Asthma and Immunology
American College of Allergy, Asthma and Immunology
Argentine Association of Allergy and Clinical Immunology
Argentine Society of Allergy and Immunopathology
Australasian Society of Clinical Immunology and Allergy
Austrian Society of Allergology and Immunology
Azerbaijan Society for Asthma, Allergy and Clinical Immunology
Bangladesh Society of Allergy and Immunology
Belarus Association of Allergology & Clinical Immunology
Belgian Society of Allergology and Immunology
Brazilian Society of Allergy and Immunopathology
British Society for Allergy and Clinical Immunology
Bulgarian National Society of Allergology
Canadian Society of Allergy and Clinical Immunology
Chilean Society of Allergy and Immunology
Chinese Society of Allergology
Colombian Allergy, Asthma, and Immunology Association
Croatian Society of Allergology and Clinical Immunology
Cuban Society of Allergy, Asthma and Clinical Immunology
Czech Society of Allergology and Clinical Immunology
Danish Society for Allergology
Dutch Society of Allergology
Egyptian Society of Allergy and Clinical Immunology
Egyptian Society of Pediatric Allergy and Immunology
Finnish Society of Allergology and Clinical Immunology
French Society of Allergology
Georgian Association of Allergology and Clinical Immunology
German Society for Allergology and Clinical Immunology
Hellenic Society of Allergology and Clinical Immunology
Honduran Society of Allergy and Clinical Immunology
Hong Kong Institute of Allergy
Hungarian Society of Allergology and Clinical Immunology
Icelandic Society of Allergy and Immunology
Indian College of Allergy, Asthma and Applied Immunology
Indonesian Society for Allergy and Immunology
Iranian Society of Asthma and Allergy
Israel Association of Allergy and Clinical Immunology
Italian Society for Allergology and Clinical Immunology
Japanese Society of Allergology
Jordanian Society for Allergy and Clinical Immunology
Korean Academy of Allergy, Asthma and Clinical Immunology
Kuwait Society of Allergy and Clinical Immunology
Latvian Association of Allergists
Lebanese Society of Allergy and Immunology
Malaysian Society of Allergy and Immunology
Mexican College of Allergy and Clinical Immunology
Mexican College of Pediatricians Specialized in Allergy and Clinical Immunology
Moldavian Society of Allergology & Immunology
Mongolian Society of Allergology
Moroccan Society of Allergology and Clinical Immunology
Norwegian Society of Allergology and Immunopathology
Panamanian Association of Allergology and Clinical Immunology
Paraguayan Society of Immunology and Allergy
Peruvian Society of Allergy and Immunology
Philippine Society of Allergy, Asthma and Immunology
Polish Society of Allergology
Portuguese Society of Allergology and Clinical Immunology
Romanian Society of Allergology and Clinical Immunology
Russian Association of Allergology and Clinical Immunology
Serbian Association of Allergologists and Clinical Immunologists
Slovenian Association for Allergology and Clinical Immunology
Swedish Association for Allergology
Allergy and Clinical Immunology Society (Singapore)
Allergy Society of South Africa
Spanish Society of Allergology and Clinical Immunology
Allergy & Immunology Society of Sri Lanka
Swiss Society of Allergology and Immunology
Allergy, Asthma and Immunology Society of Thailand
Tunisian Society of Respiratory Diseases and Allergology
Turkish National Society of Allergy and Clinical Immunology
Ukrainian Association of Allergologists and Clinical Immunologists
Uruguayan Society of Allergology
Venezuelan Society of Allergy, Asthma and Immunology
Vietnam Association of Allergy, Asthma and Clinical Immunology
Zimbabwe Allergy Society

Associate Member Societies

Allergy Society of Kenya
Ecuadorian Society of Allergy, Asthma, and Immunology
Indian Academy of Allergy
Taiwan Academy of Pediatric Allergy Asthma Immunology

Affiliate Organizations

British Society for Immunology
GA²LEN Global Allergy and Asthma European Network
International Association of Asthmology (Interasma)
International Primary Care Respiratory Group (IPCRG)
Southern European Allergy Societies (SEAS)

Regional Organizations

Asia Pacific Association of Allergy, Asthma and Clinical Immunology
Asia Pacific Association of Pediatric Allergy, Respirology and Immunology
Commonwealth of Independent States Society of Immunology
European Academy of Allergy and Clinical Immunology
Latin American Society of Allergy, Asthma and Immunology
Save the Dates!

WAC 2015
XXIII World Allergy Congress
14–17 October 2015
Seoul, Korea

www.worldallergy.org/wac2015

A meeting of in collaboration with
Symposium Sponsors

Supported by Educational Grants From

![Genentech](image1.png)
![MERCK](image2.png)
![REGENERON](image3.png)
![ViroPharma](image4.png)

Sponsored by

![Boehringer Ingelheim](image5.png)
![Respiratory](image6.png)
![Mylan](image7.png)
![SANOFI](image8.png)
![dbv technologies](image9.png)
![CIRCASSIA](image10.png)
![Ora](image11.png)
![GREER](image12.png)
![MedImmune](image13.png)

Contact Us

WAO Secretariat
World Allergy Organization
555 East Wells Street, Suite 1100
Milwaukee, WI 53202 United States
Phone: +1 414 276 1791
Fax: +1 414 276 3349
symposium@worldallergy.org
www.worldallergy.org/symposium2013

Follow us on [Facebook](#) [Twitter](#) [LinkedIn](#)
Join the conversation: #WAO2013